Post-transplant cyclophosphamide (PTCy) is increasingly used for graft-versus-host disease (GVHD) prophylaxis in both HLA-matched (matched-PTCy) and haplotype-mismatched (haplo-PTCy) hematopoietic stem cell transplantation (HCT), but the effects of PTCy on immune reconstitution in different donor settings remain incomp...
Michela Ansuinelli, H. Kim, Francesco Malfona et al.· Blood Advances· 0 citations
Solid tumors evade immunotherapy because of immunosuppressive microenvironments that limit immune cell persistence and function. Although interleukin-12 (IL-12) potently activates antitumor immunity, its clinical use has been constrained by systemic toxicity. Here we engineered a CAR natural killer (NK) cell platform t...
Mubin Tarannum, K. Dinh, Mila Stanojevic et al.· Cancer Discovery· 0 citations
LIME bridged effector and tumor cells, induced transcriptional programs of T cell activation, metabolism and proliferation, and enhanced cytotoxicity across cancer cell lines and patient-derived organoids, establishing LIME as a versatile living therapeutic platform for programmable, tumor-restricted immune orchestrati...
Shao-Bo Yang, Anna Clara Bader, S. Sendker et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.